What is Seaport Therapeutics 's R&D?

Seaport Therapeutics (SPTX) reported R&D of $21.43M in Q1 2026.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Seaport Therapeutics SPTX R&D

R&D at other companies

RepligenRGEN

$14.46M+19.3%

Sensata TechnologiesST

$31.9M-13.3%

AppFolioAPPF

$49.63M+13.4%

SynapticsSYNA

$94.5M+6.7%

TFX

TeleflexTFX

$44.39M+75.5%

Silicon LaboratoriesSLAB

$88.59M+0.4%

Segments

By product

See full

Glyph Allo Direct Research And Development Expenses$8.3M-21.2%

Glyph Ago Direct Research And Development Expenses$6.49M-38.4%

Glyph2BLSD Direct Research And Development Expenses$582K-94.5%

Other financials

Income statement

See full

Operating income-$27.5M-70.2%

Net income-$25.4M-93.6%

EPS (diluted)-$10.34-83.0%

Balance sheet

See full

Cash & equivalents$52.9M—

Total debt$5.3M—

Total equity-$115.6M-220%

Total assets$227.7M—

Cash flow

See full

Operating cash flow-$20.2M+0.2%

CapEx--100%

Free cash flow-$20.2M+0.4%

Valuation

See full

Market cap$972.65M—

Enterprise value$925.08M—

Returns & leverage

See full

Debt / equity-0×—

Current ratio13.2×—

Where this comes from

Reported directly by Seaport Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Seaport Therapeutics ’s 10-Q, filed June 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Seaport Therapeutics 's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Seaport Therapeutics 's R&D?: Seaport Therapeutics (SPTX) reported R&D of $21.43M in Q1 2026.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.